armodafinil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4501 112111-43-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nuvigil
  • CEP-10953
  • armodafinil
  • R-modafinil
  • Molecular weight: 273.35
  • Formula: C15H15NO2S
  • CLOGP: 0.94
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 60.16
  • ALOGS: -2.64
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.06 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
June 5, 2007 FDA CEPHALON

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sleep apnoea syndrome 171.67 15.50 90 10905 22111 46652956
Pre-existing condition improved 149.91 15.50 57 10938 6555 46668512
Anxiety 139.82 15.50 192 10803 181765 46493302
Depression 123.91 15.50 175 10820 169929 46505138
Suicidal ideation 107.50 15.50 96 10899 56286 46618781
Somnambulism 77.98 15.50 33 10962 5004 46670063
Therapeutic response unexpected 73.97 15.50 46 10949 15570 46659497
Multiple sclerosis relapse 63.51 15.50 63 10932 42062 46633005
Feeling abnormal 60.76 15.50 107 10888 124953 46550114
Feeling jittery 56.15 15.50 34 10961 10974 46664093
Cataplexy 53.47 15.50 17 10978 1146 46673921
Headache 49.65 15.50 233 10762 478119 46196948
Memory impairment 49.51 15.50 75 10920 77262 46597805
Enuresis 48.06 15.50 18 10977 1982 46673085
Somnolence 43.04 15.50 106 10889 156415 46518652
Blood pressure increased 42.76 15.50 93 10902 126573 46548494
Snoring 41.76 15.50 19 10976 3423 46671644
Initial insomnia 40.03 15.50 20 10975 4432 46670635
Insomnia 39.47 15.50 106 10889 164818 46510249
Panic attack 37.60 15.50 34 10961 20208 46654859
Narcolepsy 37.50 15.50 13 10982 1146 46673921
Tremor 35.76 15.50 82 10913 115557 46559510
Surgery 34.33 15.50 38 10957 28747 46646320
Sensorimotor disorder 31.66 15.50 9 10986 413 46674654
Hangover 28.75 15.50 11 10984 1284 46673783
Gaze palsy 28.73 15.50 11 10984 1287 46673780
Stress 26.14 15.50 45 10950 51506 46623561
Bruxism 25.50 15.50 13 10982 3004 46672063
Feeling drunk 25.11 15.50 14 10981 3873 46671194
Migraine 24.27 15.50 52 10943 69974 46605093
Death 24.25 15.50 26 10969 335522 46339545
Acute kidney injury 23.75 15.50 13 10982 235842 46439225
Drug tolerance 21.91 15.50 12 10983 3206 46671861
Oropharyngeal blistering 21.87 15.50 8 10987 824 46674243
Stevens-Johnson syndrome 21.53 15.50 27 10968 23270 46651797
Impaired driving ability 21.41 15.50 13 10982 4211 46670856
Neutropenia 21.24 15.50 4 10991 143200 46531867
Weight decreased 20.49 15.50 101 10894 210748 46464319
Therapeutic product effect increased 20.21 15.50 8 10987 1022 46674045
Fall 19.87 15.50 139 10856 328958 46346109
Irritability 19.83 15.50 29 10966 28917 46646150
Hypotension 19.16 15.50 16 10979 232573 46442494
Multiple sclerosis 18.69 15.50 26 10969 24765 46650302
Abnormal dreams 18.57 15.50 17 10978 10262 46664805
Substance use 18.53 15.50 6 10989 429 46674638
Sleep paralysis 18.06 15.50 6 10989 465 46674602
Hypoaesthesia 17.81 15.50 65 10930 118804 46556263
Mania 17.79 15.50 17 10978 10829 46664238
Palpitations 17.71 15.50 56 10939 95203 46579864
Renal failure 17.21 15.50 3 10992 113591 46561476
Victim of spousal abuse 16.86 15.50 3 10992 14 46675053
Unevaluable event 16.81 15.50 35 10960 46140 46628927
Toxicity to various agents 15.74 15.50 16 10979 211750 46463317
General physical health deterioration 15.61 15.50 4 10991 115765 46559302
Vitamin D deficiency 15.57 15.50 16 10979 11118 46663949

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sleep apnoea syndrome 115.86 23.25 51 3550 16806 29932071
Anxiety 55.74 23.25 61 3540 89810 29859067
Depression 48.61 23.25 57 3544 90380 29858497
Somnambulism 47.75 23.25 17 3584 3197 29945680
Rash 44.27 23.25 81 3520 191808 29757069
Insomnia 43.91 23.25 55 3546 93281 29855596
Pre-existing condition improved 43.16 23.25 14 3587 1987 29946890
Suicidal ideation 42.52 23.25 35 3566 36079 29912798
Somnolence 39.24 23.25 53 3548 96710 29852167
Feeling abnormal 32.50 23.25 37 3564 56719 29892158
Therapeutic response unexpected 28.38 23.25 16 3585 8887 29939990
Blood pressure increased 27.02 23.25 38 3563 71890 29876987
Sleep-related eating disorder 24.73 23.25 6 3595 294 29948583
Feeling jittery 24.33 23.25 11 3590 3837 29945040

Pharmacologic Action:

SourceCodeDescription
ATC N06BA13 NERVOUS SYSTEM
PSYCHOANALEPTICS
PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
Centrally acting sympathomimetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D000697 Central Nervous System Stimulants
MeSH PA D065701 Cytochrome P-450 CYP3A Inducers
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D064690 Wakefulness-Promoting Agents
CHEBI has role CHEBI:35337 analeptic drug
CHEBI has role CHEBI:77567 wake-promoting drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Narcolepsy indication 60380001 DOID:8986
Sleepiness Due To Obstructive Sleep Apnea indication
Sleepiness Due To Shift Work Sleep Disorder indication
Suicidal thoughts contraindication 6471006
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Left ventricular hypertrophy contraindication 55827005
Hepatic failure contraindication 59927004
Psychotic disorder contraindication 69322001
Mania contraindication 231494001
Mitral valve prolapse contraindication 409712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.23 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter INHIBITOR IC50 5.50 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR EC50 6.92 WOMBAT-PK
Cytochrome P450 2C19 Enzyme WOMBAT-PK
Cytochrome P450 1A2 Enzyme WOMBAT-PK
Alpha-1B adrenergic receptor GPCR WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.49 CHEMBL

External reference:

IDSource
V63XWA605I UNII
D03215 KEGG_DRUG
4026237 VANDF
C0066677 UMLSCUI
CHEBI:77590 CHEBI
CHEMBL1201192 ChEMBL_ID
DB06413 DRUGBANK_ID
D000077408 MESH_DESCRIPTOR_UI
9690109 PUBCHEM_CID
8474 INN_ID
641465 RXNORM
116668 MMSL
23941 MMSL
241076 MMSL
d06842 MMSL
012231 NDDF
428694009 SNOMEDCT_US
429452005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3090 TABLET 50 mg ORAL NDA AUTHORIZED GENERIC 30 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3092 TABLET 150 mg ORAL NDA AUTHORIZED GENERIC 30 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3093 TABLET 200 mg ORAL NDA AUTHORIZED GENERIC 30 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3094 TABLET 250 mg ORAL NDA AUTHORIZED GENERIC 30 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3431 TABLET 50 mg ORAL ANDA 31 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3432 TABLET 150 mg ORAL ANDA 31 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0378-3433 TABLET 250 mg ORAL ANDA 31 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0781-8029 TABLET 50 mg ORAL NDA AUTHORIZED GENERIC 28 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0781-8037 TABLET 150 mg ORAL NDA AUTHORIZED GENERIC 28 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0781-8045 TABLET 200 mg ORAL NDA AUTHORIZED GENERIC 28 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 0781-8053 TABLET 250 mg ORAL NDA AUTHORIZED GENERIC 28 sections
NUVIGIL HUMAN PRESCRIPTION DRUG LABEL 1 16590-345 TABLET 150 mg ORAL NDA 24 sections
NUVIGIL HUMAN PRESCRIPTION DRUG LABEL 1 16590-394 TABLET 250 mg ORAL NDA 24 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 42254-014 TABLET 50 mg ORAL NDA 24 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 55700-510 TABLET 250 mg ORAL NDA AUTHORIZED GENERIC 31 sections
ARMODAFINIL HUMAN PRESCRIPTION DRUG LABEL 1 59651-047 TABLET 200 mg ORAL NDA 27 sections
ARMODAFINIL HUMAN PRESCRIPTION DRUG LABEL 1 61919-562 TABLET 150 mg ORAL NDA authorized generic 17 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 61919-770 TABLET 150 mg ORAL ANDA 17 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 63459-205 TABLET 50 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 63459-215 TABLET 150 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 63459-220 TABLET 200 mg ORAL NDA 29 sections
Nuvigil HUMAN PRESCRIPTION DRUG LABEL 1 63459-225 TABLET 250 mg ORAL NDA 29 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 63629-7390 TABLET 150 mg ORAL NDA AUTHORIZED GENERIC 30 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 63629-7403 TABLET 250 mg ORAL NDA AUTHORIZED GENERIC 30 sections
Armodafinil Human Prescription Drug Label 1 65862-805 TABLET 50 mg ORAL ANDA 31 sections
Armodafinil Human Prescription Drug Label 1 65862-806 TABLET 150 mg ORAL ANDA 31 sections
Armodafinil Human Prescription Drug Label 1 65862-807 TABLET 250 mg ORAL ANDA 31 sections
Armodafinil Human Prescription Drug Label 1 65862-998 TABLET 200 mg ORAL ANDA 31 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 68180-569 TABLET 50 mg ORAL ANDA 28 sections
Armodafinil HUMAN PRESCRIPTION DRUG LABEL 1 68180-571 TABLET 150 mg ORAL ANDA 28 sections